Lexicon Pharmaceuticals, Inc.

NASDAQ: LXRX
$1.94
-$0.07 (-3.5%)
Closing price July 2, 2020
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Lexicon Pharma shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm.
Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on the Marketing Authorization of Zynquista...
Vodafone, Lexicon Pharmaceuticals, Amneal Pharmaceuticals, and Maiden Holding had all posted new 52-week lows by noon Friday.
Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of sell the news.
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald's and...
These top picks from Wedbush offer varying degrees of risk and upside. The fact that they are not crowded momentum plays makes them far more attractive for the rest of 2017 and into next year.
Equifax, New York REIT, Opko, and Lexicon Pharma all posted new 52-week lows Thursday.
Hewlett Packard Enterprise, Equifax, New York REIT, and Lexicon Pharmaceuticals all posted new 52-week lows on Wednesday.
The top analyst upgrades, downgrades and other research calls from Monday Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna and Lexicon Pharma.
Shares of Lexicon Pharmaceuticals saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes.
Here are three biotech companies that not only have data that could prove to be huge, but their shares have been absolutely hammered over the last year, offering aggressive accounts the best entry...